FAD-DOX

FAD-DOX is a nanoparticle-based formulation in which doxorubicin, an anthracycline chemotherapeutic, is encapsulated in an amphiphilic dendrimer micelle known as FAD (fluorinated amphiphilic dendrimer). This nanosystem is specifically designed to improve doxorubicin delivery and efficacy against cancer, particularly in pancreatic ductal adenocarcinoma (PDAC) models. Compared to free doxorubicin and commercial liposomal doxorubicin (e.g., Caelyx), FAD-DOX nanomicelles exhibit higher drug loading (>90%), superior stability, and enhanced cellular uptake through macropinocytosis, resulting in consistently potent antiproliferative activity across diverse primary human pancreatic cancer cells. FAD-DOX shows a superior therapeutic index and avoids observable toxicity in preclinical studies, with enhanced accumulation in tumor tissues and effective inhibition of tumor growth[3].